My conclusion is - insufficient data. We need details of US sales and more sales in higher-margin Australia. Also how are sales progressing compared to planned targets? SVA is now my smallest holding (12th out of 12).
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025